Thanks for digging up those numbers. I seem to remember Mayo also mentioning that the abeta 42/40 ratio in plasma corresponds close to ninety percent with the same ratio in CSF, which I think is an accepted biomarker.
As I said the abeta 42/40 performance is helpful and so are other biomarkers including MRI, the gene expression levels associated with AD/PDD that Missling also mentioned at Cowen etc. all as part of the peer reviewed publication, when eventually published. All that in combination with acceptance of the one co-primary and secondary outcome measures. Recall that Anavex is going for full approval rather than than the EMA equivalent of accelerated approval with confirmatory study, so the focus will be on the trials declared endpoints and SAP order.
News 
Market Data 
Discover 
